We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Uric Acid Levels Predict Death in Acute Coronary Syndrome

By HospiMedica International staff writers
Posted on 02 May 2012
Elevated levels of uric acid are predictive of one-year mortality in patients with acute coronary syndrome (ACS), according to a new study.

Researchers at the German Heart Center (Deutsches Herzzentrum; Munich, Germany) conducted a study involving 5,124 patients with ACS who underwent percutaneous coronary intervention (PCI) to evaluate whether uric acid levels have any prognostic value. More...
The participants were classified into four uric acid quartiles: quartile 1 (1.3 to <5.3 mg/dL), quartile 2 (5.3 to <6.3 mg/dL), quartile 3 (6.3 to <7.5 mg/dL), and quartile 4 (7.5 to 18.4 mg/dL). Of the participants, 1,629 had acute ST-segment elevation myocardial infarction (STEMI), 1,332 had acute non-STEMI, and 2,163 had unstable angina. The primary end point was one-year mortality.

The results showed that during follow-up, there were 450 deaths: 80 deaths in quartile 1, 77 in quartile 2, 72 in quartile 3, and 221 in quartile 4. The researchers found that uric acid measurement improved the discriminatory power of the predictive model regarding one-year mortality. After adjustment for traditional cardiovascular (CV) risk factors, renal function, and inflammatory status, the association between uric acid and mortality remained significant, with a 12% increase in the adjusted risk for one-year mortality for every 1 mg/dL increase in the uric acid level. The study was published in the May 1, 2012, issue of the American Journal of Cardiology.

“Elevated levels of uric acid are an independent predictor of one-year mortality across the whole spectrum of patients with acute coronary syndromes treated with percutaneous coronary intervention,” concluded lead author Gjin Ndrepepa, MD, and colleagues.

Related Links:

German Heart Center





Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.